Literature DB >> 21778901

Diffuse uremic tumoral calcinosis in a patient on long-term hemodialysis.

Nessrine Akasbi1, Tarik Sqalli Houssaini, Samira Rabhi, Mariam Lahlou, Amal Boukhrissa, Latifa Tahiri, Chakib El Maaroufi, Rhizlane Berrady, Taoufik Harzy, Wafaa Bono.   

Abstract

Tumoral calcinosis is an uncommon and severe complication of hemodialysis therapy. The most important pathogenic factor involved in uremic tumoral calcinosis is an increase in calcium-phosphorus product, not necessarily related to hyperparathyroidism. We report here a patient on hemodialysis who presented with increasing multifocal and uncommon sites of massive calcifications. The patient was examined, and a diagnosis of uremic tumor calcinosis was made. The patient was treated with the noncalcemic phosphate binder sevelamer, a strict diet, multiple hemodialysis sessions per week, and a low calcium dialysate, with improvement on biological findings a decrease in the volume of some tumors on his fingers and a global stable disease. Some nodes in hands and feet disappeared; in other sites, their diameter was reduced, and the largest nodule decreased from 5- to 2-cm diameter.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778901     DOI: 10.1097/RHU.0b013e3182288acd

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  1 in total

1.  Amelioration of uremic tumoral calcinosis with high-flux hemodialysis treatment.

Authors:  Tingting Xie; Yong Zhang; Xiangling Tang; Mengying Chen; Weiru Zhang
Journal:  Int Urol Nephrol       Date:  2014-03-05       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.